Last reviewed · How we verify
NCT02404584: GenCInibs-Suni
The Pharmacokinetic Variability of Sunitinib in Patients With Metastatic Renal Cancer
trial testing Blood drawn for genotyping in Kidney Neoplasms in 43 participants. Completed in 21 May 2019.
21 May 2019
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire de Nīmes |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 43 |
| Start date | 29 December 2015 |
| Primary completion | 21 May 2019 |
| Estimated completion | 21 May 2019 |
| Sites | 3 locations across France |
Drugs / interventions tested
- Blood drawn for genotyping
- Blood drawn for pharmacokinetic measures — full drug profile →
Conditions studied
- Kidney Neoplasms — all drugs for Kidney Neoplasms →
Sponsor
Centre Hospitalier Universitaire de Nīmes
Who can join
18 and older, any sex, with Kidney Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to determine the percentage of patients with a plasma concentration of sunitinib remaining at equilibrium (\[Suni\]REq) greater than 100 ng / ml (effective concentration according to the current literature).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Genetic polymorphisms of <i>VEGFR2</i> and <i>FGFR2</i> genes are associated with exposure to sunitinib and cardiovascular toxicity.
Mbatchi LC, Leenhardt F, Occean BV, Perrin O, et al · · 2025 · PMID 41277563 · DOI 10.1080/14622416.2025.2579001
Verify or expand the search:
- PubMed search for NCT02404584
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Neoplasms
Currently open trials in the same condition.
- NCT06676527 — Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma · recruiting
- NCT06536439 — Planning Operative Strategy Using a Digital Renal Artery Clamping Tool · NA · recruiting
- NCT06715878 — Zero Ischemia Robot-Assisted MWA Assisted Suture-less Tumor Enucleation of RCC With T1 Stage · NA · recruiting
- NCT05218811 — Cryaoablation Assisted Partial Nephrectomy a Non Ischemic Approach · NA · recruiting
- NCT06126159 — MRI Functional Imaging Characteristics and Fat Quantification of CT-fat-free Renal Neoplasms: Relationships With Histolo · NA · active not recruiting
Other Centre Hospitalier Universitaire de Nīmes trials
Trials by the same sponsor.
- NCT07403474 — Combined Use of a Respiratory Multiplex PCR and Algorithm-based Therapy to Improve Early Optimization of Antibiotic Ther · Phase 4 · not yet recruiting
- NCT07455981 — Work Organization and Gambling Addiction · not yet recruiting
- NCT07403500 — Evaluation of the Short-term Effectiveness of Spinal Manipulation to Treat Acute and Subacute Low Back Pain. · NA · not yet recruiting
- NCT07342010 — Bicarbonate Addition to Lidocaine-Epinephrine in Surgery Under WALANT · Phase 4 · not yet recruiting
- NCT07305727 — A Radiomic MRI Predictive Model for Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02404584 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nīmes
- Last refreshed: 4 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02404584.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing